Here are the 10-K annual reports from FibroBiologics, Inc. (FBLG) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow FBLG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBLG filings page.
FibroBiologics, Inc. filed Amendment No. 1 to its 2025 annual report to add the previously omitted Part III sections on directors, executive officers, compensation, security ownership, related‑party transactions and auditor fees. The company states the amendment does not change any prior financial results or other disclosures in the original 2025 report.
FibroBiologics, Inc. is a clinical-stage biotech company developing fibroblast-based cell therapies for chronic diseases such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and longevity-related indications. Its approach uses allogeneic fibroblast single cells and spheroids as a scalable alternative to mesenchymal stem cells.
Lead program CYWC628 targets diabetic foot ulcers, with IND-enabling studies completed and a twelve-week Phase 1/2 trial in Australia planned for the first quarter of 2026. CYMS101 for multiple sclerosis has completed a five-patient Phase 1 safety study in Mexico, with a U.S. Phase 1/2 IND planned for the first half of 2026.
CybroCell™ for degenerative disc disease has supporting animal data and prior FDA IND clearance, while CYPS317 for psoriasis has an FDA Phase 1/2 IND filed on December 30, 2025. Early research programs include CYTER915 for thymus and spleen regeneration, a cancer initiative (TCB190), and an artificial pancreatic organoid program.